13th Call for proposals 2017 - Innovative Medicines Initiative 2 Joint Undertaking - H2020-JTI-IMI2 H2020-JTI-IMI2-2017-13-TWO-STAGE Open!

Objectives

The Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU) has been created following the principles below:

  • Research related to the future of medicine should be undertaken in areas where societal, public health and biomedical industry competitiveness goals are aligned and require the pooling of resources and greater collaboration between the public and private sectors, with the involvement of Small- and Medium- sized Enterprises (SMEs).
  • The scope of the initiative should be expanded to all areas of life science research and innovation.
  • The areas should be of public health interest, as identified by the World Health Organisation (WHO) report on priority medicines for Europe and the World

Actions

This call covers the following topics:

  • IMI2-2017-13-01: Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
  • IMI2-2017-13-02: Genome-Environment Interactions in Inflammatory Skin Disease
  • IMI2-2017-13-03: The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
  • IMI2-2017-13-04: Mitochondrial Dysfunction in Neurodegeneration
  • IMI2-2017-13-05: Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative
  • IMI2-2017-13-06: A sustainable European induced pluripotent stem cell platform
  • IMI2-2017-13-07: Linking digital assessment of mobility to clinical endpoints to support regulatory acceptance and clinical practice
  • IMI2-2017-13-08: Human Tumour Microenvironment Immunoprofiling
  • IMI2-2017-13-09: ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology and Breastfeeding to Improve Outcomes Now
  • IMI2-2017-13-10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
  • IMI2-2017-13-11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
  • IMI2-2017-13-12: Pilot programme on a Clinical Compound Bank for Repurposing: Cardiovascular diseases and diabetes
  • IMI2-2017-13-13: Pilot programme on a Clinical Compound Bank for Repurposing: Respiratory diseases
  • IMI2-2017-13-14: Pilot programme on a Clinical Compound Bank for Repurposing: Neurodegenerative diseases
  • IMI2-2017-13-15: Pilot programme on a Clinical Compound Bank for Repurposing: Rare/orphan diseases

European community funding

The Community provisional funding available for the call for proposals is:

  • 223,05 Million EUR (Global Budget)

All the important deadlines

  • 28 February 2018 - in one month (Deadline for the presentation of proposals)
  • 06 September 2018 - in 7 months (Deadline for the presentation of proposals)

Further information about the call

Official webpage of the call

Useful documents

  • Call for Proposals (Legal base)

Organisations eligible to participate

Opened to the following bodies or institutes with legal status established in the covered areas:

  • Any legal organisation

Covered areas

Bodies or institutes must have their registered legal seat in one of the countries taking part in the Programme which are:

  • European Union (EU)

Directorate-Generale responsible

Directorate-General for Research

Related calls for proposals

Related calls

Explore other programmes